| 名称 | BRL-15572 dihydrochloride |
| 描述 | BRL-15572 dihydrochloride (BRL 15573 dihydrochloride) is a 5-HT1D receptor antagonist with pKi of 7.9, also shows a considerable affinity at 5-HT1A and 5-HT2B receptors, exhibiting 60-fold selectivity over 5-HT1B receptor. |
| 细胞实验 | [35S]GTPγS binding studies. [35S]GTPγS binding studies in CHO cells expressing the h5-HT1B or h5-HT1D receptors are performed. In brief, membranes from 1 × 106 cells are preincubated at 30°C for 30 minutes, in HEPES buffer (HEPES [20 mM], MgCl2 [3 mM], NaCl [100 mM], ascorbate [0.2 mM]), containing GDP (10 μ M), with or without BRL-15572. The reaction is started by the addition of 10 μL of [35S]GTPγS (100 pM, assay concentration) followed by a further 30 minutes incubation at 30°C. Non-specific binding is determined by addition of unlabelled GTPγS (10 μM), prior to the addition of cells. The reaction is stopped by rapid filtration using Whatman GF/B grade filters followed by five washes with ice-cold HEPES buffer. Radioactivity is determined by liquid scintillation spectrometry.(Only for Reference) |
| 体外活性 | BRL-15572 displays high affinity and selectivity for h5-HT1D receptors. BRL-15572 has 60-fold higher affinity for h5-HT1D than 5-HT1B receptors. BRL-15572 binds to h5-HT1B and h5-HT1D receptors with pKB of less than 6 and 7.1, respectively. BRL-15572 stimulates [35S]GTP γ S binding in both cell lines, with potencies that correlated with their receptor binding affinities in both h5-HT1B and h5-HT1D receptor expressing cell lines. BRL-15572 reveals receptor binding affinities for 5-HT1A, 5-HT1B, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT6 and 5-HT7 with pKi of 7.7, 6.1, 5.2, 6.0, 6.6, 7.4, 6.2, 5.9 and 6.3, respectively. In the h5-HT1D cell line, both BRL-15572 (1 μM) shifts the 5-HT concentration response curve with pKB of 7.1, respectively. BRL-15572 does have moderately high affinity at human 5-HT1A and 5-HT2B receptors. [1] In human atrial appendages, the electrically evoked tritium overflow is inhibited by 5-HT in a manner susceptible to antagonism by BRL-15572 (300 nM; 23 times Ki at h5-HT1D receptors). [2] The inhibitory effect of 5-HT on the K+-evoked overflow of glutamate is antagonized by the h5-HT1D receptor ligand BRL-15572. BRL-15572 (1 μM) is unable to modify the effect of 5-HT at the autoreceptor regulating [3H]5-HT release. [3] The selective 5-HT1D/1B receptor antagonist BRL 15572 inhibits the effect of the agonist L-694 247. [4] |
| 体内活性 | In diabetic pithed rats, administration of the selective 5-HT1D receptor antagonist BRL-15572 (2 mg/kg) does not modify the decreased HR induced by vagal electrical stimulation. The effects of L-694,247 (50 μg/kg), a selective agonist for non-rodent 5-HT1B and 5-HT1D receptors, on the vagally induced bradycardia are not apparent after pretreatment with BRL-15572. [5] |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 89 mg/mL (185.47 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : 38 mg/mL (79.19 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (6.88 mM), Sonication is recommended.
|
| 关键字 | Serotonin Receptor | Inhibitor | inhibit | h5-HT1D | BRL-15573 Dihydrochloride | BRL15573 Dihydrochloride | BRL-15573 | BRL15573 | BRL-15572 Dihydrochloride | BRL15572 Dihydrochloride | BRL15572 dihydrochloride | BRL-15572 | BRL15572 | BRL 15573 Dihydrochloride | BRL 15573 | BRL 15572 Dihydrochloride | BRL 15572 dihydrochloride | BRL 15572 | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT7 | 5-HT2B | 5-HT2A | 5-HT1D | 5-HT1A | 5-HT Receptor | 5HT Receptor |
| 相关产品 | Cefaclor monohydrate | Tryptamine hydrochloride | pCPA methyl ester hydrochloride | Sevoflurane | Cloperastine hydrochloride | Venlafaxine hydrochloride | Alverine citrate | Dapoxetine hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Clozapine N-Oxide | 1,8-Cineole |
| 相关库 | 抑制剂库 | 抗帕金森病化合物库 | 血管生成库 | 经典已知活性库 | 已知活性化合物库 | 抗阿尔茨海默症化合物库 | 5-羟色胺分子库 | GPCR靶点分子库 | 神经退行性疾病化合物库 | 膜蛋白靶向化合物库 | 疼痛相关化合物库 | 表型筛选靶点鉴定库 |